Eversana Intouch
FEBRUARY 1, 2023
Are more prescriptions being written and fulfilled to validate the time, money, and resoures allocated? Are those ‘seamless brand experiences’ integrating the right mix of digital tools and one-on-one personal engagements actually accelerating patients’ time to therapy and delivering business impact?
Pharmaceutical Technology
MARCH 30, 2023
The overdose death rate in the US increased more than 250% from 1999 to 2019, as per a Canada-US joint white paper on substance use and harms. Between 1999 and 2021, overdose deaths from synthetic opioids excluding methadone increased 97-fold, and prescription opioid overdose deaths increased 4.9-fold,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 14, 2022
A study of public tenders for prescription medicines between 2014 and 2019 shows a fall in multi-criteria tenders rewarding “environmental” attributes and an average weighting of only 5% (see Figure 2). Where tenders are concerned, greater weight should be given to sustainable criteria, which is well understood, but poorly implemented.
Pharmaceutical Technology
OCTOBER 28, 2022
For more information on this, please download our white paper. For more information, please download our white paper. Regardless of whether a drug product is intended for mass populations or certain prescriptions, QbD should always be followed in its development. “In
pharmaphorum
JUNE 29, 2022
The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth. Non-COVID prescription medicines didn’t stop launching during the pandemic — approvals by both the FDA and the EMA were, in fact historically high in both 2020 and 2021. The scope of the problem.
Pharmaceutical Technology
FEBRUARY 1, 2023
Currently, GSK’s GSK 3844766A (RSVPreF3 OA) and Pfizer’s vaccine candidate RSVpreF (PF-06928316) may reach FDA approval first, having Prescription Drug User Fee Act (PDUFA) dates of May 3 and May 31, respectively. In a Phase III trial, GSK’s vaccine demonstrated a 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6%.
Evolve Your Success
NOVEMBER 28, 2023
We have a fantastic white paper for any of your readers at HidoHealth.com. A lot of the relationships that we are growing and communicating to are often the executive leaders that are able to read a white paper or maybe they don’t come across a video. We have an 80% reduction over 12 months. You can jump in there.
Expert insights. Personalized for you.
59 
Let's personalize your content